Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Inotiv (NOTV – Research Report) today. The company’s shares closed last Friday at $4.27.
According to TipRanks, Hewitt is an analyst with an average return of -1.5% and a 44.64% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, Inotiv, and Apyx Medical.
Currently, the analyst consensus on Inotiv is a Strong Buy with an average price target of $10.75.
NOTV market cap is currently $110.1M and has a P/E ratio of -3.31.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inotiv (NOTV) Company Description:
Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
